The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters - PubMed

Collaborators, Affiliations

• PMID: 24025520
• DOI: 10.1097/PAS.0b013e318299f0fb

The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters

Brett Delahunt et al. Am J Surg Pathol. 2013 Oct.

Abstract

The International Society of Urological Pathology 2012 Consensus Conference made recommendations regarding classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. Issues relating to prognostic factors were coordinated by a workgroup who identified tumor morphotype, sarcomatoid/rhabdoid differentiation, tumor necrosis, grading, and microvascular invasion as potential prognostic parameters. There was consensus that the main morphotypes of renal cell carcinoma (RCC) were of prognostic significance, that subtyping of papillary RCC (types 1 and 2) provided additional prognostic information, and that clear cell tubulopapillary RCC was associated with a more favorable outcome. For tumors showing sarcomatoid or rhabdoid differentiation, there was consensus that a minimum proportion of tumor was not required for diagnostic purposes. It was also agreed upon that the underlying subtype of carcinoma should be reported. For sarcomatoid carcinoma, it was further agreed upon that if the underlying carcinoma subtype was absent the tumor should be classified as a grade 4 unclassified carcinoma with a sarcomatoid component. Tumor necrosis was considered to have prognostic significance, with assessment based on macroscopic and microscopic examination of the tumor. It was recommended that for clear cell RCC the amount of necrosis should be quantified. There was consensus that nucleolar prominence defined grades 1 to 3 of clear cell and papillary RCCs, whereas extreme nuclear pleomorphism or sarcomatoid and/or rhabdoid differentiation defined grade 4 tumors. It was agreed upon that chromophobe RCC should not be graded. There was consensus that microvascular invasion should not be included as a staging criterion for RCC.

Similar articles

• Advances in renal neoplasia: recommendations from the 2012 International Society of Urological Pathology Consensus Conference.

  Delahunt B, Srigley JR, Montironi R, Egevad L. Delahunt B, et al. Urology. 2014 May;83(5):969-74. doi: 10.1016/j.urology.2014.02.004. Epub 2014 Mar 22. Urology. 2014. PMID: 24661331

• A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis.

  Delahunt B, McKenney JK, Lohse CM, Leibovich BC, Thompson RH, Boorjian SA, Cheville JC. Delahunt B, et al. Am J Surg Pathol. 2013 Mar;37(3):311-22. doi: 10.1097/PAS.0b013e318270f71c. Am J Surg Pathol. 2013. PMID: 23348209

• [Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)].

  Kristiansen G, Delahunt B, Srigley JR, Lüders C, Lunkenheimer JM, Gevensleben H, Thiesler T, Montironi R, Egevad L. Kristiansen G, et al. Pathologe. 2015 May;36(3):310-6. doi: 10.1007/s00292-014-2030-z. Pathologe. 2015. PMID: 25398389 German.

• A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade.

  Paner GP, Amin MB, Alvarado-Cabrero I, Young AN, Stricker HJ, Moch H, Lyles RH. Paner GP, et al. Am J Surg Pathol. 2010 Sep;34(9):1233-40. doi: 10.1097/PAS.0b013e3181e96f2a. Am J Surg Pathol. 2010. PMID: 20679882

• [The WHO/ISUP grading system for renal carcinoma].

  Moch H. Moch H. Pathologe. 2016 Jul;37(4):355-60. doi: 10.1007/s00292-016-0171-y. Pathologe. 2016. PMID: 27271258 German.

Cited by

• Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation.

  Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Adibi M, et al. Urol Oncol. 2015 Oct;33(10):427.e17-23. doi: 10.1016/j.urolonc.2015.04.011. Epub 2015 May 23. Urol Oncol. 2015. PMID: 26004164 Free PMC article.

• A Computed Tomography-Based Radiomics Nomogram to Preoperatively Predict Tumor Necrosis in Patients With Clear Cell Renal Cell Carcinoma.

  Jiang Y, Li W, Huang C, Tian C, Chen Q, Zeng X, Cao Y, Chen Y, Yang Y, Liu H, Bo Y, Luo C, Li Y, Zhang T, Wang R. Jiang Y, et al. Front Oncol. 2020 May 29;10:592. doi: 10.3389/fonc.2020.00592. eCollection 2020. Front Oncol. 2020. PMID: 32547934 Free PMC article.

• Contemporary review of papillary renal cell carcinoma-current state and future directions.

  Castillo VF, Trpkov K, Saleeb R. Castillo VF, et al. Virchows Arch. 2024 Sep;485(3):391-405. doi: 10.1007/s00428-024-03865-x. Epub 2024 Jul 12. Virchows Arch. 2024. PMID: 38995356 Review.

• Comparison of clinicopathologic parameters and oncologic outcomes between type 1 and type 2 papillary renal cell carcinoma.

  Le X, Wang XB, Zhao H, Chen RF, Ge P. Le X, et al. BMC Urol. 2020 Sep 15;20(1):148. doi: 10.1186/s12894-020-00716-0. BMC Urol. 2020. PMID: 32933514 Free PMC article.

• Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.

  Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon JC, Ficial M, Frontera OA, George S, Powles T, Donskov F, Harrison MR, Barthélémy P, Tykodi SS, Kocsis J, Ravaud A, Rodriguez-Cid JR, Pal SK, Murad AM, Ishii Y, Saggi SS, McHenry MB, Rini BI. Tannir NM, et al. Clin Cancer Res. 2021 Jan 1;27(1):78-86. doi: 10.1158/1078-0432.CCR-20-2063. Epub 2020 Sep 1. Clin Cancer Res. 2021. PMID: 32873572 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wolters Kluwer

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information